Additional Administration Option Approved for Nuplazid Capsules
Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson disease psychosis.
Dementia
Anticholinergics Linked to Increased Dementia Risk
Physicians should carefully weigh the risks against the potential benefits before prescribing anticholinergics, according to investigators.
Type of Anesthesia Not Linked to Dementia Risk in Older Adults
Dementia risk did not differ by general, regional anesthesia in seniors undergoing elective surgery.
Metformin May Slow Cognitive Decline in Seniors With T2DM
Cognitive decline slower, dementia risk reduced in seniors with diabetes receiving metformin
CNS-Active Meds Often Prescribed for Older Adults With Dementia
Overall, Rx filled for antidepressants in 49.8 percent, opioids in 29.8 percent, anxiolytics in 26.8 percent
Pimavanserin sNDA Under Review for Dementia-Related Psychosis
The FDA has accepted for filing the supplemental New Drug Application (sNDA) for pimavanserin (Nuplazid®; Acadia) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Pimavanserin sNDA Submitted for Dementia-Related Psychosis
Acadia Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for pimavanserin (Nuplazid®) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Early Metformin Initiation Does Not Appear to Cut Dementia Risk
Previous research has suggested that treatment with metformin may potentially lower the risk of dementia, however whether the timing of treatment impacts this result remains unclear.
Anticholinergic Meds for Overactive Bladder May Up Dementia Risk
Among patients with overactive bladder (OAB), anticholinergic medication use appears to be associated with an increased risk of new onset dementia when compared with beta-3 agonist use, according to the findings of a retrospective population-based cohort study.
Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.
